Friday 16 October 2026 Export LRMR’s income statement to Excel — free account

Larimar Therapeutics, Inc.

In the quarter to June 2026, EPS grew 26.8% and free cash flow fell 127.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.99 0.00 0.00%

Follow LRMR

Alert me

Market cap: $206.7M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 25.72

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	4	—	—	—	—	1	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 53.79%

Capital & Financial Ratios $m

Market Cap 206.73

Revenue —

Net Income (172.60)

Free Cash Flow (156.10)

Net Debt (156.27)

Current Ratio 4.70

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 0.00

P/B ratio 1.62

Past 5Y EPS Growth —

This Y EPS Growth 39.62%

Next Y EPS Growth 14.62%

Next Y revenue growth —

Next 5Y EPS Growth 38.33%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

P/B against its own 10 years 51.09%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	87	183	137	156
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	90	195	142	161

	2023	2024	2025	Q'26
Payables	1	2	5	8
ST’ Debt	—	—	—	—
Other	—	—	—	—
	10	24	65	34

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(7.44%)	(2.73%)	(11.04%)

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(45)	(44)	—	—	—
’25	(27)	(19)	(29)	(39)	(113)
’24	(10)	(14)	(25)	(22)	(71)
’23	(8)	(7)	(9)	(9)	(33)
’22	(8)	(7)	(6)	(7)	(28)
’21	(11)	(11)	(12)	(8)	(42)
’20	(9)	(12)	(11)	(10)	(42)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(45)	(44)	—	—	—
’25	(27)	(19)	(29)	(39)	(113)
’24	(10)	(14)	(25)	(22)	(71)
’23	(8)	(7)	(9)	(10)	(34)
’22	(8)	(8)	(6)	(7)	(28)
’22	—	—	—	—	(28)
’21	(11)	(11)	(12)	(8)	(42)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.31)	(0.30)	—	—	—
’25	(0.46)	(0.41)	(0.61)	(0.73)	(2.27)
’24	(0.27)	(0.34)	(0.24)	(0.45)	(1.32)
’23	(0.15)	(0.19)	(0.21)	(0.30)	(0.84)
’22	(0.49)	(0.47)	(0.37)	(0.21)	(1.37)
’21	(0.76)	(0.79)	(0.92)	(0.50)	(2.95)
’20	(1.20)	(1.21)	(0.64)	(0.89)	(3.57)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	34.68	38.16	55.20	7.44	7.43	7.00	1.53	2.18	3.01	1.61	Analyst estimates 2026–2028 Powerpack
	High	146.16	65.52	148.26	65.40	25.87	23.95	11.05	6.85	13.68	5.37
People
People	Employees	32	35	38	7	28	31	26	42	65	71
	Revenue/emp, $m	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—
	EBT	(58)	(52)	(61)	(23)	(42)	(51)	(35)	(37)	(81)	(166)
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Net income	(58)	(52)	(61)	(23)	(42)	(51)	(35)	(37)	(81)	(166)
	Depreciation	1	0	0	0	0	0	0	(2)	(5)	(1)
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	Earnings	(25.45)	(22.81)	(22.81)	(3.80)	(3.57)	(2.95)	(1.37)	(0.84)	(1.32)	(2.27)
	Cash flow	(22.86)	(19.16)	(19.18)	(3.73)	(3.55)	(2.45)	(1.07)	(0.76)	(1.16)	(1.55)
	Capex	(0.29)	(0.02)	(0.04)	(0.01)	(0.01)	(0.02)	0.00	0.00	(0.01)	0.00
	Free cash flow	(23.15)	(19.18)	(19.22)	(3.74)	(3.56)	(2.47)	(1.07)	(0.77)	(1.16)	(1.55)
	Book value	53.53	34.23	34.74	(0.11)	7.55	3.75	4.31	1.86	2.80	1.07
	Shares, m	2	2	3	6	12	17	26	44	61	73
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—
	P/S	—	—	—	—	—	—	—	—	—	—
	P/B	—	—	—	—	—	—	—	—	—	—
	EV/Sales	—	—	—	—	—	—	—	—	—	—
	EV/FCF	—	—	—	—	—	—	—	—	—	—
Cash, $m
Cash, $m	Operating cash flow	(52)	(44)	(51)	(23)	(42)	(42)	(28)	(33)	(71)	(113)
	Capex	(1)	0	0	0	0	0	0	0	(1)	0
	Free cash flow	(53)	(44)	(52)	(23)	(42)	(42)	(28)	(34)	(71)	(113)
Balance, $m
Balance, $m	Working capital	121	98	108	(1)	89	63	110	81	171	77
	Total debt	4	20	15	8	6	5	5	—	—	—
	Net debt	(129)	(82)	(103)	(1)	(93)	(70)	(118)	(87)	(183)	(137)
	Shareholders’ equity	122	78	93	(1)	90	64	111	82	172	78
Returns, %
Returns, %	ROA	(36.09)	(43.88)	(54.00)	(36.44)	(77.32)	(55.23)	(34.48)	(33.24)	(54.43)	(95.75)
	ROIC	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	ROE	(39.80)	(52.04)	(71.57)	(49.97)	(95.47)	(65.72)	(40.33)	(38.36)	(63.58)	(132.59)

Negative figures in brackets.

All 10 years →

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LXEO Lexeo Therapeutics, Inc.	$226.6M	— (loss-making)	— (loss-making)	—	n/m	+35.58% (above 0%: growing)	0.00%	0.00%	Compare
KROS Keros Therapeutics, Inc.	$220.1M	— (loss-making)	— (loss-making)	−99.83% (below 0%: shrinking)	n/m	+32.19% (above 0%: growing)	100.00%	0.00%	Compare
CAMP CAMP4 Therapeutics Corporation	$216.5M	— (loss-making)	— (loss-making)	+18.84% (above 0%: growing)	n/m	−23.90% (below 0%: shrinking)	100.00%	(752.11%)	Compare
PYXS Pyxis Oncology, Inc.	$215.3M	— (loss-making)	— (loss-making)	—	n/m	−5.46% (below 0%: shrinking)	100.00%	0.00%	Compare
EVMN Evommune Inc.	$215.2M	— (loss-making)	— (loss-making)	—	n/m	+21.78% (above 0%: growing)	100.00%	0.00%	Compare
MGNX MacroGenics, Inc.	$214.7M	— (loss-making)	— (loss-making)	+377.97% (above 0%: growing)	n/m	+12.88% (above 0%: growing)	100.00%	(42.19%)	Compare
ZNTL Zentalis Pharmaceuticals, Inc.	$212.1M	— (loss-making)	— (loss-making)	—	n/m	−9.06% (below 0%: shrinking)	100.00%	0.00%	Compare
LRMR Larimar Therapeutics, Inc.	$206.7M	— (loss-making)	—	—	n/m	−127.63% (below 0%: shrinking)	0.00%	0.00%
ADCT ADC Therapeutics SA	$190.2M	— (loss-making)	— (loss-making)	+2.17% (above 0%: growing)	n/m	+50.98% (above 0%: growing)	87.80%	(132.03%)	Compare
Median of peers	$215.2M	—	—	+10.51%	—	+17.33%	100.00%	0.00%

All 614 Biotechnology stocks →

Larimar Therapeutics, Inc. (LRMR) key facts

Larimar Therapeutics, Inc. (LRMR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, LRMR traded at $1.99, a market capitalization of $206.7 million.
Return on equity was −132.6% and debt-to-equity 0.00.

Source: company filings (standardised) and stockrow calculations.